Literature DB >> 18570300

Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide.

Brian H Kushner1, Michael P Laquaglia, Kim Kramer, Shakeel Modak, Nai-Kong V Cheung.   

Abstract

An 8-year old child had a pelvic MYCN-nonamplified neuroblastoma (NB) with retroperitoneal nodal extension. Multi-modality therapy achieved complete remission (CR). Small recurrences confined to left supraclavicular nodes were treated with surgery alone at 4.9, 6.5, 7.5, 9.5, and 12.9 years from diagnosis. Monitoring through 12 months after the last resection showed CR. When she returned 34 months later (16.8 years from diagnosis), she had massive disease in the left neck and upper trunk, without osteomedullary metastases. Salvage therapy featured 11 cycles of temozolomide. She developed myelodysplastic syndrome with 45,XX,der(7)t(7;21) (p15;q11),-21 at age 24 and refused treatment; 19 months later she was transfusion-dependent but her NB remained in CR. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18570300      PMCID: PMC4010138          DOI: 10.1002/pbc.21658

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  20 in total

1.  Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors.

Authors:  M D Megonigal; N K Cheung; E F Rappaport; P C Nowell; R B Wilson; D H Jones; K Addya; D G Leonard; B H Kushner; T M Williams; B J Lange; C A Felix
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

Authors:  Sonali M Smith; Michelle M Le Beau; Dezheng Huo; Theodore Karrison; Ronald M Sobecks; John Anastasi; James W Vardiman; Janet D Rowley; Richard A Larson
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

3.  Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group.

Authors:  H S Nicholson; M Krailo; M M Ames; N L Seibel; J M Reid; W Liu-Mares; L G Vezina; A G Ettinger; G H Reaman
Journal:  J Clin Oncol       Date:  1998-09       Impact factor: 44.544

4.  Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.

Authors:  R L Saylors; K C Stine; J Sullivan; J L Kepner; D A Wall; M L Bernstein; M B Harris; R Hayashi; T J Vietti
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

5.  Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.

Authors:  Roy E Smith; John Bryant; Arthur DeCillis; Stewart Anderson
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

Review 6.  Leukemias related to treatment with DNA topoisomerase II inhibitors.

Authors:  C A Felix
Journal:  Med Pediatr Oncol       Date:  2001-05

Review 7.  Therapy-related leukemia associated with alkylating agents.

Authors:  S M Davies
Journal:  Med Pediatr Oncol       Date:  2001-05

8.  Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment.

Authors:  Mary V Relling; James M Boyett; Javier G Blanco; Susana Raimondi; Frederick G Behm; John T Sandlund; Gaston K Rivera; Larry E Kun; William E Evans; Ching-Hon Pui
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

9.  Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.

Authors:  Lars M Wagner; Kristine R Crews; Lisa C Iacono; Peter J Houghton; Christine E Fuller; M Beth McCarville; Robert E Goldsby; Karen Albritton; Clinton F Stewart; Victor M Santana
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

Review 10.  Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure.

Authors:  E G Levine; C D Bloomfield
Journal:  Semin Oncol       Date:  1992-02       Impact factor: 4.929

View more
  4 in total

Review 1.  Aging of hematopoietic stem cells: DNA damage and mutations?

Authors:  Bettina M Moehrle; Hartmut Geiger
Journal:  Exp Hematol       Date:  2016-07-08       Impact factor: 3.084

2.  Stem Cell-Specific Mechanisms Ensure Genomic Fidelity within HSCs and upon Aging of HSCs.

Authors:  Bettina M Moehrle; Kalpana Nattamai; Andreas Brown; Maria C Florian; Marnie Ryan; Mona Vogel; Corinna Bliederhaeuser; Karin Soller; Daniel R Prows; Amir Abdollahi; David Schleimer; Dagmar Walter; Michael D Milsom; Peter Stambrook; Matthew Porteus; Hartmut Geiger
Journal:  Cell Rep       Date:  2015-12-10       Impact factor: 9.423

Review 3.  Treatment-related myelodysplasia in patients with primary brain tumors.

Authors:  Joachim M Baehring; Peter W Marks
Journal:  Neuro Oncol       Date:  2012-03-29       Impact factor: 12.300

Review 4.  Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy.

Authors:  Bernd Kaina; Geoffrey P Margison; Markus Christmann
Journal:  Cell Mol Life Sci       Date:  2010-08-18       Impact factor: 9.261

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.